# Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

> **NCT05916911** · PHASE4 · UNKNOWN · sponsor: **Catalysis SL** · enrollment: 120 (estimated)

## Conditions studied

- Papilloma Viral Infection
- CIN1
- LSIL, Low Grade Squamous Intraepithelial Lesion

## Interventions

- **DIETARY_SUPPLEMENT:** Glizigen
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05916911
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-07
- **Primary completion:** 2024-06-04
- **Final completion:** 2025-01-08
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05916911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05916911, "Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05916911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*